Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDMONASDAQ:CMRXNASDAQ:CRVSNYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDMOAvid Bioservices$12.50+0.1%$12.50$6.61▼$12.51$799.18M1.391.43 million shs3.07 million shsCMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.72 million shsN/ACRVSCorvus Pharmaceuticals$3.89-7.6%$3.79$1.75▼$10.00$265.18M0.57814,947 shs7.68 million shsRCUSArcus Biosciences$7.94-6.5%$8.80$6.50▼$18.98$841.19M0.83872,276 shs3.75 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDMOAvid Bioservices0.00%0.00%0.00%0.00%+75.00%CMRXChimerix0.00%0.00%0.00%+0.35%+874.89%CRVSCorvus Pharmaceuticals0.00%-1.77%+2.37%+22.33%+113.74%RCUSArcus Biosciences0.00%-8.32%-11.54%+0.99%-47.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDMOAvid Bioservices0.9006 of 5 stars1.00.00.04.51.51.70.6CMRXChimerix0.6707 of 5 stars1.00.00.04.10.61.70.6CRVSCorvus Pharmaceuticals2.5251 of 5 stars3.51.00.00.02.92.50.6RCUSArcus Biosciences3.0217 of 5 stars4.43.00.00.01.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDMOAvid Bioservices 2.00Hold$12.25-1.96% DownsideCMRXChimerix 2.00Hold$8.53-0.08% DownsideCRVSCorvus Pharmaceuticals 3.00Buy$15.00285.60% UpsideRCUSArcus Biosciences 2.89Moderate Buy$21.29167.95% UpsideCurrent Analyst Ratings BreakdownLatest CRVS, RCUS, CMRX, and CDMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025CRVSCorvus PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$12.00 ➝ $11.005/9/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.005/9/2025RCUSArcus BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.005/8/2025RCUSArcus BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/7/2025RCUSArcus BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.005/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $26.004/23/2025RCUSArcus BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $14.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDMOAvid Bioservices$139.91M5.71$0.15 per share80.92$3.02 per share4.14CMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94CRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/ARCUSArcus Biosciences$258M3.26N/AN/A$5.30 per share1.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDMOAvid Bioservices-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%6/30/2025 (Estimated)CMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%8/11/2025 (Estimated)CRVSCorvus Pharmaceuticals-$62.29M-$0.98N/AN/AN/AN/A-24.04%-13.90%8/5/2025 (Estimated)RCUSArcus Biosciences-$283M-$4.19N/AN/AN/A-258.94%-70.58%-32.97%8/4/2025 (Estimated)Latest CRVS, RCUS, CMRX, and CDMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRVSCorvus Pharmaceuticals-$0.13-$0.13N/A-$0.13N/AN/A5/6/2025Q1 2025RCUSArcus Biosciences-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDMOAvid BioservicesN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDMOAvid Bioservices3.581.300.92CMRXChimerixN/A6.336.33CRVSCorvus PharmaceuticalsN/A4.904.90RCUSArcus Biosciences0.095.375.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDMOAvid Bioservices97.16%CMRXChimerix45.42%CRVSCorvus Pharmaceuticals46.64%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipCDMOAvid Bioservices3.05%CMRXChimerix13.10%CRVSCorvus Pharmaceuticals31.30%RCUSArcus Biosciences9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDMOAvid Bioservices32063.96 million62.01 millionOptionableCMRXChimerix9093.80 million78.15 millionOptionableCRVSCorvus Pharmaceuticals3068.17 million46.83 millionOptionableRCUSArcus Biosciences500105.89 million95.72 millionOptionableCRVS, RCUS, CMRX, and CDMO HeadlinesRecent News About These CompaniesArcus Biosciences (NYSE:RCUS) Trading Down 6.3% - Here's What HappenedJune 27 at 4:36 PM | marketbeat.comIncyte, FDA, Sun Pharma and more—Chutes & LaddersJune 27 at 3:58 PM | fiercebiotech.comFArcus Biosciences Announces New Employment Inducement Grants - Business WireJune 26, 2025 | businesswire.comPrecision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’June 26, 2025 | msn.comBrokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price at $24.13June 26, 2025 | americanbankingnews.comPrecision BioSciences Shares Surge Following FDA Rare Pediatric Disease DesignationJune 25, 2025 | msn.comPrecision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%June 25, 2025 | msn.comArcus Biosciences, Inc. (RCUS) Cash Flow - Yahoo FinanceJune 24, 2025 | finance.yahoo.comRCUS Arcus Biosciences, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comArcus Biosciences Announces New Employment Inducement GrantsJune 24, 2025 | businesswire.comArcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Moderate Buy" by AnalystsJune 23, 2025 | marketbeat.comThe trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gambleJune 13, 2025 | fiercebiotech.comFArcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?June 11, 2025 | marketbeat.comStock Traders Purchase Large Volume of Call Options on Arcus Biosciences (NYSE:RCUS)June 11, 2025 | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsJune 10, 2025 | businesswire.comResearch Analysts Offer Predictions for RCUS FY2026 EarningsJune 10, 2025 | marketbeat.comH.C. Wainwright maintains Buy rating for Arcus Biosciences stockJune 4, 2025 | investing.comArcus Biosciences, Inc. (NYSE:RCUS) Short Interest Up 25.2% in MayJune 4, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Trading 10.6% Higher - Here's What HappenedJune 4, 2025 | marketbeat.comNuveen Asset Management LLC Has $1.96 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)June 4, 2025 | marketbeat.comArcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s WeliregJune 2, 2025 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRVS, RCUS, CMRX, and CDMO Company DescriptionsAvid Bioservices NASDAQ:CDMO$12.50 +0.02 (+0.12%) Closing price 02/5/2025Extended Trading$12.50 0.00 (0.00%) As of 02/5/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.Chimerix NASDAQ:CMRX$8.54 0.00 (0.00%) As of 04/21/2025Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Corvus Pharmaceuticals NASDAQ:CRVS$3.89 -0.32 (-7.60%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.93 +0.04 (+1.03%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Arcus Biosciences NYSE:RCUS$7.94 -0.56 (-6.54%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$14.00 +6.06 (+76.23%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
